Keywords: Heptares, Novartis, StaR technology, GPCR targets, Research
Heptares in up to $200 million deal with Novartis for StaR technology for drug leads against a GPCR target
Article | 13 October 2009
UK-based Heptares Therapeutics, a drug discovery company focused on G-protein-coupled receptor (GPCR) targets, has entered into an option agreement with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
